Volume 1.44 | Nov 19

Prostate Cell News 1.44, November 19, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

New Drug Targets Vitamin D Receptors in Hormone Resistant Prostate Cancers: Promising Results From First Clinical Trial 
A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies. [Press release from the European CanCer Organization (ECCO) discussing data presented at the 22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium on Molecular Targets and Cancer Therapeutics]

EasySep_645x110_v01



SPECIAL FEATURE

Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at [email protected]

Follow us on Twitter! @ProstateCell



SCIENCE NEWS

PARP Inhibitor, MK-4827, Shows Anti-Tumour Activity in First Trial in Humans
A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans. Some patients with a range of solid tumours, many of whom had been treated unsuccessfully for their cancer with other therapies, have seen their tumours shrink or stabilise for periods of between 46 days to more than a year. [Press release from the European CanCer Organization (ECCO) discussing data presented at the 22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium on Molecular Targets and Cancer Therapeutics]

Detecting Cancer With the Prick of a Finger
Researchers have created a micro device that could both decrease the amount of blood and time needed to test for cancer-markers in a patient’s blood. [Press release from Brigham Young University discussing online prepublication in Lab on a Chip]

Watch Procedure Now  

Culture and Characterize Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies

 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 



CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Biological Activity of 4-Substituted Methoxybenzoyl-Aryl-Thiazole (SMART): An Active Microtubule Inhibitor
Researchers recently reported a class of 4-Substituted Methoxybenzoyl-Aryl-Thiazoles (SMART) that exhibited great in vitro potency and broad spectrum cellular cytotoxicity. Evaluation of the in vitro and in vivo anti-cancer activities of three SMART compounds, SMART-H (H), SMART-F (F) and SMART-OH (OH) with varying substituents at the 4-position of aryl ring, demonstrated that they bind potently to the colchicine binding site in tubulin, inhibit tubulin polymerization, arrest cancer cells in G2/M phase of the cell cycle, and induce their apoptosis. [Cancer Res]

The BH3 Mimetic ABT-737 Induces Cancer Cell Senescence
ABT-737, a small molecule cell-permeable Bcl-2 antagonist that acts by mimicking BH3 proteins, induces apoptotic cell death in multiple cancer types. However, when incubated with this agent many solid tumor cell lines do not undergo apoptosis. The current study reveals a novel mechanism whereby ABT-737 when added to apoptosis-resistant cancer cells has profound biologic effects. [Cancer Res]

The Bcl-2-Beclin 1 Interaction in (-)-Gossypol-Induced Autophagy Versus Apoptosis in Prostate Cancer Cells
The results provide new insights into the mode of cell death induced by Bcl-2 inhibitors, which could facilitate the rational design of clinical trials by selecting patients who are most likely to benefit from the Bcl-2-targeted molecular therapy. [Autophagy]

Microdevices Integrating Affinity Columns and Capillary Electrophoresis for Multibiomarker Analysis in Human Serum
Here, researchers developed integrated microdevices with an affinity column and capillary electrophoresis channels to isolate and quantitate a panel of proteins in complex matrices. [Lab Chip]

Proteomics Profiling of Microdissected Low- and High-Grade Prostate Tumors Identifies Lamin A as a Discriminatory Biomarker
Researchers used two-dimensional differential gel electrophoresis in combination with laser capture microdissection and MALDI-TOF/TOF mass spectrometry to determine differentially abundant proteins and candidate biomarkers in prostate cancer. [J Proteome Res]

Neuroendocrine Prostate Cancer Xenografts With Large-Cell and Small-Cell Features Derived From a Single Patient’s Tumor: Morphological, Immunohistochemical, and Gene Expression Profiles
Eight tumor fragments from the salvage pelvic exenteration specimen of a patient with castrate-resistant prostate carcinoma were subcutaneously implanted into 6- to 8-week-old male CB17 SCID mice. Serial tissue sections and tissue microarrays of the resulting MDA PCa 144 xenograft lines were used for histopathologic and immunohistochemical characterization of the xenografts and their tissue of origin. [Prostate]

Selenoprotein-P is Down-Regulated in Prostate Cancer, Which Results in Lack of Protection Against Oxidative Damage
The main goal of the study was to assess whether selenoprotein-P protects prostate cells from reactive oxygen species in prostate carcinogenesis. [Prostate]

CLINICAL RESEARCH

Disease and Host Characteristics as Predictors of Time to First Bone Metastasis and Death in Men with Progressive Castration-Resistant Nonmetastatic Prostate Cancer
In men with progressive castration-resistant prostate cancer and no detectable metastases, baseline prostate-specific antigen (PSA) was significantly associated with time to first bone metastasis, bone metastasis-free survival, and overall survival. [Cancer]

Risk of Prostate Cancer is Not Associated With Levels of C-Reactive Protein and Other Commonly Used Markers of Inflammation
Most population-based studies studied the association between inflammation and prostate cancer by assessing C-reactive protein. Since these findings have shown inconsistent results, researchers aimed to also study different markers that have been commonly taken as indications of inflammation. [Int J Cancer]



INDUSTRY NEWS

Exelixis Reports Promising Interim Data from Patients with Castration-Resistant Prostate Cancer Treated with XL184
Exelixis, Inc. reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase II adaptive randomized discontinuation trial (RDT). [Exelixis, Inc. Press Release]

Synta Announces STA-9584 (Vascular Disrupting Agent) Recommended for $1 Million in DoD Funding for Study in Advanced Prostate Cancer
Synta Pharmaceuticals Corp. announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer. [Synta Pharmaceuticals Corp. Press Release]

Prostate Cancer Drug Gets Lukewarm Review
There is only “moderate”’ evidence that the newly approved prostate cancer drug Provenge helps patients, according to an analysis done for Medicare that was made public. [The New York Times]





EVENTS (Listed by Date)

Cancer Pharmacogenetics: Personalizing Medicine
November 22-24, 2010
Madrid, Spain

American Association for Cancer Research (AACR) Tumor Immunology – Basic and Clinical Advances
November 30-December 3, 2010
Miami, United States

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

11th Annual Meeting of the Society of Urologic Oncology (SUO): Extraordinary Opportunities for Discovery
December 8-9, 2010
Bethesda, United States

The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

American Association for Cancer Research (AACR) Targeting PI3K/mTOR Signaling in Cancer
February 24-27, 2011
San Francisco, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

MENA Oncology Conference
March 11-12, 2011
Cairo, Egypt

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

National Cancer Institute (NCI) Cancer Research Imaging Camp
June 19-24, 2011
St. Louis, United States

4th Annual Advances in Biodetection & Biosensors Conference and Exhibition
June 30-July 1, 2011
Hamburg, Germany

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)


Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us